Eugia Pharma Receives USFDA Approval for Naloxone HCl Injection Prefilled Syringe 2 mg/2 mL
Published: January 14, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Naloxone HCl Injection Prefilled Syringe 2 mg/2 mL.
Indications for this product include:
- Complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids;
- Diagnosis of suspected or known acute opioid overdosage;
- May be useful as an adjunctive agent to increase blood pressure in the management of septic shock.
Refer to package insert for full prescribing information.